Alexion Pharmaceuticals Inc (ALXN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Published : Dec-2017

No. of Pages : 137

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Alexion Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 12
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Alexion Acquires Patents Of An Investigational Therapy For Infants From Orphatec 15
Venture Financing 17
Moderna Therapeutics Raises USD450 Million in Venture Financing 17
Synageva Biopharma Secures US$25 Million In Equity Financing 19
Private Equity 20
TRC Capital To Acquire 0.77% Stake In Alexion Pharma For US$136 Million 20
Partnerships 21
Blueprint Medicines Enters into Co-Development Agreement with Alexion Pharma 21
X-Chem Enters into Discovery Agreement with Alexion Pharma 22
Prothelia And University of Nevada, Reno Enter Into Co-Development Agreement With Alexion 23
Alexion Pharma And Moderna Therapeutics Enter Into Agreement To Develop Messenger RNA Therapeutics For Rare Diseases 25
Ensemble Therapeutics And Alexion Pharma Enter Into Agreement To Discover Macrocycle Drug Candidates 26
Synageva BioPharma Extends Co-Development Agreement With Mitsubishi Tanabe Pharma 27
Synageva BioPharma Enters Into Research Agreement With Mitsubishi Tanabe Pharma 28
Merger 29
Synageva BioPharma Completes Merger With Trimeris 29
Licensing Agreements 31
Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 31
Xencor Enters into Licensing Agreement with Alexion Pharma 32
Equity Offering 34
Synageva BioPharma Prices Public Offering of Shares for USD283 Million 34
Phaserx Raises USD5.5 Million in Private Placement of Preferred Shares 36
Synageva BioPharma Completes Public Offering Of Shares For US$211.5 Million 37
Synageva BioPharma Completes Public Offering Of Shares For US$179 Million 39
Synageva BioPharma Completes Public Offering Of Common Stock For US$118 Million 41
Synageva BioPharma Completes Public Offering Of Common Stock For US$115 Million 42
Synageva BioPharma Completes Public Offering Of Common Stock For US$90 Million 44
Acquisition 46
Alexion Pharma Acquires Synageva BioPharma for USD8.4 Billion 46
Alexion Pharma Completes Acquisition Of Enobia Pharma 48
Alexion Pharma Acquires Taligen Therapeutics 50
Alexion Pharmaceuticals Inc - Key Competitors 52
Alexion Pharmaceuticals Inc - Key Employees 53
Alexion Pharmaceuticals Inc - Locations And Subsidiaries 54
Head Office 54
Other Locations & Subsidiaries 54
Recent Developments 57
Strategy And Business Planning 57
Sep 12, 2017: Alexion Announces Restructuring to Advance Corporate Strategy 57
Financial Announcements 59
Jul 27, 2017: Alexion Reports Second Quarter 2017 Results 59
Apr 27, 2017: Alexion Reports First Quarter 2017 Results 60
Feb 16, 2017: Alexion Reports Fourth Quarter And Full Year 2016 Results And Provides Financial Guidance For 2017 61
Oct 27, 2016: Alexion Reports Third Quarter 2016 Results 63
Jul 28, 2016: Alexion Reports Second Quarter 2016 Results 65
Apr 28, 2016: Alexion Reports First Quarter 2016 Results 67
Feb 03, 2016: Alexion Reports Fourth Quarter and Full Year 2015 Results and Provides Financial Guidance for 2016 69
Corporate Communications 71
Nov 08, 2017: Alexion Appoints Francois Nader, M.D. to its Board of Directors 71
Sep 14, 2017: Alexion Adds Paul A. Friedman, M.D. to Its Board of Director 72
Jun 13, 2017: Alexion Names Paul Clancy Chief Financial Officer 73
Jun 01, 2017: Alexion Announces Additions To Executive Leadership Team 74
May 23, 2017: Alexion Announces Executive Leadership Changes 76
Mar 27, 2017: Alexion Appoints Ludwig Hantson, Ph.D., As Chief Executive Officer 78
Mar 24, 2017: Alexion submits application to Japan's MHLW to extend Soliris indication to treat gMG 79
Mar 02, 2017: Leonard Bell, M.D., Alexion's Founder, Announces Plans to Retire as Chairman and Board Member 80
Dec 13, 2016: Alexion Pharmaceuticals names David Brennan as interim CEO 82
Dec 12, 2016: Alexion Pharmaceuticals appoints interim CEO 84
Dec 12, 2016: Alexion's Board Of Directors Announces New Leadership Appointments 86
Product News 88
12/21/2016: Alexion Announces Top-Line Results from Phase 2/3 PROTECT Study of Eculizumab (Soliris) for the Prevention of Delayed Graft Function (DGF) After Kidney Transplantation 88
12/04/2016: New Data From ALXN1210 Dose-Escalation Study Presented At ASH Show Rapid And Sustained Reductions In LDH In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) 89
11/17/2016: New Data from Global aHUS Registry Presented at ASN 2016 Show a Three-Fold Reduction in Post-Transplant Dialysis in Patients Initiating Soliris (eculizumab) Treatment Prior to Transplant Compared to Initiating Treatment Post-Transplant 91
11/03/2016: Researchers to Present New Phase 1/2 Data on ALXN1210 in Patients with PNH at ASH 2016 Annual Meeting 93
Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers 94
07/14/2016: Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive Assessments in Patients with Mucopolysaccharidosis IIIB (MPS IIIB) 96
07/06/2016: Federal Court Dismisses Challenge to Constitutionality of Federal Government's Drug Price Watchdog 98
06/10/2016: Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH 99
03/03/2016: New Data Presented at WORLDSymposium 2016 Show Substantial Survival Benefit Beyond 2 Years of Age in Infants with Lysosomal Acid Lipase Deficiency Treated with Kanuma(sebelipase alfa) 100
03/03/2016: Ensemble Therapeutics Achieves Milestone 102
02/16/2016: A Statement from the Executive Officer of the Ontario Public Drug Programs on behalf of the pCPA 103
01/04/2017: Alexion Pharmaceuticals Files Form 10-Q For Third Quarter 2016 104
Product Approvals 105
Mar 08, 2017: FDA Accepts sBLA Filing of Soliris (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis 105
Jan 06, 2017: FDA Grants Orphan Drug Designation To ALXN1210 For The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria 106
Oct 19, 2016: FDA Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease 107
Sep 22, 2016: Alexion statement: NICE 2nd ECD for Strensiq (asfotase alfa) 108
Aug 29, 2016: European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease 109
Jun 01, 2016: European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) 110
Mar 28, 2016: Kanuma (sebelipase alfa) Receives Marketing Approval in Japan for Treatment of Patients with Lysosomal Acid Lipase Deficiency 111
Feb 18, 2016: NICE calls for more research into promising new drug to treat inherited rare enzyme deficiency 112
Clinical Trials 114
Mar 22, 2017: Alexion Submits Application In Japan For Soliris As A Potential Treatment For Patients With Refractory Generalized Myasthenia Gravis 114
Jan 09, 2017: Alexion Submits U.S. And EU Applications Seeking Approval Of Soliris (Eculizumab) As A Treatment For Patients With Refractory Generalized Myasthenia Gravis (GMG) 115
Nov 11, 2016: New Long-Term Data Presented at AASLD Show Reduction in Liver Fibrosis and Cirrhosis in a Cohort of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma (sebelipase alfa) 116
Oct 27, 2016: Alexion Initiates Simultaneous Registration Trials of ALXN1210 for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) 118
Oct 06, 2016: New Long-Term Data Presented at WCPGHAN 2016 Show Rapid and Sustained Improvements in Important Markers of Liver Injury and Lipid Abnormalities in Children and Adults with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma (sebelipase alfa) 120
Jul 07, 2016: New Data from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis Presented at ICNMD Annual Congress 122
Jun 10, 2016: Alexion Pharmaceuticals Presented data on ALXN1007 at 21st Congress of the European Hematology Association 124
Jun 06, 2016: Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis (gMG) 125
May 19, 2016: Researchers to Present Additional Data, Including Late-Breaking Results on ALXN1007 in Patients with GI-GVHD at EHA Annual Congress 127
Apr 04, 2016: Data Presented at ENDO 2016 Show Sustained Improvements in Survival Rates, Bone Healing, Respiratory Support and Physical Function in Children with Hypophosphatasia (HPP) Receiving Long-Term Treatment with Strensiq (asfotase alfa) 128
Jan 15, 2016: Researchers to Present New Data at ENDO 2016 Advancing the Understanding of Strensiq (asfotase alfa) in Infants, Children and Adult Patients with Hypophosphatasia (HPP) 131
Other Significant Developments 132
Jul 27, 2017: Moderna Provides Update on mRNA Rare Disease R&D Strategy 132
Jan 04, 2017: Alexion Pharmaceuticals Files Form 10-Q for Third Quarter 2016 133
Jul 15, 2016: PhRMA Welcomes Five New Member Companies 135
Jul 08, 2016: Alexion Announces 100 Million Investment in Athlone Site With Construction of New Manufacturing Facility 136
Appendix 137
Methodology 137
About GlobalData 137
Contact Us 137
Disclaimer 137

List of Tables
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Alexion Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 10
Alexion Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 12
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Alexion Acquires Patents Of An Investigational Therapy For Infants From Orphatec 15
Moderna Therapeutics Raises USD450 Million in Venture Financing 17
Synageva Biopharma Secures US$25 Million In Equity Financing 19
TRC Capital To Acquire 0.77% Stake In Alexion Pharma For US$136 Million 20
Blueprint Medicines Enters into Co-Development Agreement with Alexion Pharma 21
X-Chem Enters into Discovery Agreement with Alexion Pharma 22
Prothelia And University of Nevada, Reno Enter Into Co-Development Agreement With Alexion 23
Alexion Pharma And Moderna Therapeutics Enter Into Agreement To Develop Messenger RNA Therapeutics For Rare Diseases 25
Ensemble Therapeutics And Alexion Pharma Enter Into Agreement To Discover Macrocycle Drug Candidates 26
Synageva BioPharma Extends Co-Development Agreement With Mitsubishi Tanabe Pharma 27
Synageva BioPharma Enters Into Research Agreement With Mitsubishi Tanabe Pharma 28
Synageva BioPharma Completes Merger With Trimeris 29
Alexion Pharma Enters into Licensing Agreement with Halozyme Therapeutics 31
Xencor Enters into Licensing Agreement with Alexion Pharma 32
Synageva BioPharma Prices Public Offering of Shares for USD283 Million 34
Phaserx Raises USD5.5 Million in Private Placement of Preferred Shares 36
Synageva BioPharma Completes Public Offering Of Shares For US$211.5 Million 37
Synageva BioPharma Completes Public Offering Of Shares For US$179 Million 39
Synageva BioPharma Completes Public Offering Of Common Stock For US$118 Million 41
Synageva BioPharma Completes Public Offering Of Common Stock For US$115 Million 42
Synageva BioPharma Completes Public Offering Of Common Stock For US$90 Million 44
Alexion Pharma Acquires Synageva BioPharma for USD8.4 Billion 46
Alexion Pharma Completes Acquisition Of Enobia Pharma 48
Alexion Pharma Acquires Taligen Therapeutics 50
Alexion Pharmaceuticals Inc, Key Competitors 52
Alexion Pharmaceuticals Inc, Key Employees 53
Alexion Pharmaceuticals Inc, Subsidiaries 54

List of Figures
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 8
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Alexion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Alexion Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 12

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Alexion Pharmaceuticals Inc (ALXN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027